Compounds > iosmin
Page last updated: 2024-12-08

iosmin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

iosmin: a constrast agent; contains 350 mg iodine/mL [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID213045
CHEMBL ID2104971
CHEBI ID177740
SCHEMBL ID2482449
MeSH IDM0418335

Synonyms (32)

Synonym
CHEBI:177740
iosimenol
5-[[3-[3-carbamoyl-n-(2,3-dihydroxypropyl)-5-(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanilino]-3-oxopropanoyl]-(2,3-dihydroxypropyl)amino]-3-n-(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
iosmin
D08934
iosimenol (inn/usan)
181872-90-2
qpg0485vls ,
bp13 cpd
5,5'-((1,3-dioxo-1,3-propanediyl)bis((2,3-dihydroxypropyl)imino))bis(n-(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
bp 13 cpd
bp-13
5,5'-(propanedioylbis((2,3-dihydroxypropyl)imino)bis(n-(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
icj-3393
bp-13 cpd
icj3393
icj 3393
iosimenol [usan:inn]
mp-3047-04
unii-qpg0485vls
n,n'-bis(3-carbamoyl-5-(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodophenyl)-n,n'-bis(2,3-dihydroxypropyl)malonamide
CHEMBL2104971
iosimenol [usan]
1,3-benzenedicarboxamide, 5,5'-((1,3-dioxo-1,3-propanediyl)bis((2,3-dihydroxypropyl)imino))bis(n-(2,3-dihydroxypropyl)-2,4,6-triiodo-
iosimenol [inn]
SCHEMBL2482449
DTXSID90939496
5,5'-{(1,3-dioxopropane-1,3-diyl)bis[(2,3-dihydroxypropyl)azanediyl]}bis[n~1~-(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboximidic acid]
5,5'-[(1,3-dioxo-1,3-propanediyl)bis[(2,3-dihydroxypropyl)imino]]bis[n-(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide]
DLPPIGPJCKKVBA-UHFFFAOYSA-N
Q15999935
AKOS040752094

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events were recorded throughout the study up to 14 days after dosing."( The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium Iosimenol 340 injection in healthy human subjects.
Hogstrom, B; Kelsch, B; Meurer, K, 2015)		0.42
" Thirty-two adverse events were observed in 14 subjects."( The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium Iosimenol 340 injection in healthy human subjects.
Hogstrom, B; Kelsch, B; Meurer, K, 2015)		0.42

Pharmacokinetics

ExcerptReferenceRelevance
"Iodinated contrast media (CM) have molecular and pharmacokinetic properties likely to make them highly dialyzable."( Hemodialysis clearance of iosimenol, a novel iso-osmolar radiographic contrast medium.
Hirao, Y; Hogstrom, B; Ikei, N; Kashiyama, E; Kohno, M; Umehara, K, 2014)		0.4
" The area under the plasma concentration curve and the peak plasma concentration was proportional to dose, while clearance was independent of dose."( The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium Iosimenol 340 injection in healthy human subjects.
Hogstrom, B; Kelsch, B; Meurer, K, 2015)		0.42
"The connection between pharmacokinetic models and system theory has been established for a long time."( A Signal Processing Approach to Pharmacokinetic Data Analysis.
Aguilar-Ros, A; Martín, FR; Montejo, C; Moreno, MAP; Sorzano, COS, 2021)		0.62

Dosage Studied

ExcerptRelevanceReference
" In each dosing group, six subjects received Iosimenol 340 and two subjects received placebo."( The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium Iosimenol 340 injection in healthy human subjects.
Hogstrom, B; Kelsch, B; Meurer, K, 2015)		0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amidobenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's6 (60.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.93 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index163.17 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (52.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (18.18%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
iodine
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..		2.9210diatomic iodinenutrient
iodixanol
iodixanol: dimeric contrast media; structure given in first source. iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.		2.9740organoiodine compoundradioopaque medium
iohexol
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.		3.6630benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iomeprol
iomeprol: structure given in first source. iomeprol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.		2.0610benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iopromide
iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.		3.3520dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
ioversol
[no description available]		2.0610amidobenzoic acid
ioxaglate
Ioxaglic Acid: A low-osmolar, ionic contrast medium used in various radiographic procedures.. ioxaglic acid : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an acetyl(methyl)amino group at the 5-position.		2.9210benzenedicarboxamide;
benzoic acids;
organoiodine compound		radioopaque medium
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.9210taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
iopamidol
Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.		2.0610benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Arrhythmia
[description not available]		02.0810
Arteriosclerosis, Coronary
[description not available]		02.0810
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.0810
Coronary Artery Disease
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.		02.0810
Exanthem
[description not available]		03.511
Itching
[description not available]		03.511
Exanthema
Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.		03.511
Pruritus
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.		03.511
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		02.0310